China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership with Yinjia Biosciences, a protein reagents and diagnostic products developer based in Shanghai. The agreement aims to enhance the development and industrialization of cell and gene therapy (CGT) by leveraging the strengths of both companies.
Partnership Details
Under the agreement, Yinjia Bio will provide Porton with high-quality core key protein raw materials and testing reagent product services related to quality control and evaluation systems. Both parties will jointly promote the development and industrialization of CGT, marking a significant step in advancing this promising field of medicine.
Porton’s CDMO Platform
Founded in 2018, Porton boasts an end-to-end gene and cell therapy CDMO service platform. The platform covers a broad range of therapeutic areas, including plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy, and live bacterial therapy. This comprehensive service offering positions Porton as a leading provider in the CGT space.
Yinjia Bio’s Product Portfolio
Yinjia Bio, established in 2020, has developed over 50 high-end proteins, including a calcium-regulated nerve phosphatase (PP2B), adenosyl se, non-viral carrier-specific protein for cell therapy, and a novel antibody for concomitant diagnosis of liver cancer and gastric cancer. The company’s products also cover cell therapies, mRNA vaccines, closed-loop RNA, new drug research and development, and molecular diagnosis and concomitant diagnosis of new tumor drugs.
Strategic Implications
The partnership between Suzhou Porton Biologics and Yinjia Biosciences is a strategic move to combine expertise in protein reagents and CGT development. By collaborating, the two companies aim to accelerate the commercialization of innovative therapies and improve patient access to advanced treatments. This initiative is expected to enhance the competitive position of both companies in the global biotechnology market and contribute to the broader goal of advancing medical science.-Fineline Info & Tech
